Hanne Merritt

Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site

Robert Schier, Adrian M. McCall, Gregory P. Adams et al. · Journal of Molecular Biology · 1996 · 381 citations

Immunocytochemical Technique, Complementarity Determining Regions, Immunology +7

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

Matthew T. Burger, Sabina Pecchi, Allan S. Wagman et al. · ACS Medicinal Chemistry Letters · 2011 · 248 citations · Full text

2,4-Bismorpholino 6-Heterocyclic Pyrimidines, Pi3 Kinase Inhibitor, Orally Bioavailable Class +18

RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation

Matthew Holderfield, Hanne Merritt, John S.D. Chan et al. · Cancer Cell · 2013 · 123 citations · Full text

Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor

Darrin D. Stuart, Nanxin Li, Daniel J. Poon et al. · Cancer Research · 2012 · 52 citations

Abstract 3790, Braf Mutant Tumors, Tumor Biology +17

Design and Discovery of <i>N</i>-(2-Methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers

Gisele Nishiguchi, Alice Rico, Huw R. Tanner et al. · Journal of Medicinal Chemistry · 2017 · 44 citations · Full text

Drug Target, Kras Mutant Tumors, Kinase Inhibitors +17